Screening based proteomics and clinical verification of molecular markers of hepatocellular carcinoma subtypes.pdf

1、福建醫(yī)科大學(xué)博士學(xué)位論文 Contents Appendix ............................................................................................... 1 Abstract ..................................................................................

2、............... 3 Foreword ................................................................................................ 7 Part 1 Clinical pathological factors analysis about recurrence/metastasis of hepatocellular ca

3、rcinoma in different periods after curative resection ..................... ... .......................................................... ...... ... 14 1 Materials and Methods ...........................................

4、......................... 15 2 Results ................................................ ............................................. 18 3 Discussion.............................. ........................................

5、....................21 4 Conclusion.................................... .................................................... 30 5 References ............................................. .................................

6、......... 31 Part 2 Comparative quantitative proteomics study of hepatocellular carcinoma subtypes with different numbers ..................... ........ . ...... 39 1 Materials and methods ...............................

7、....................................... 40 2 Results ............................................... .............................................. 47 3 Discussion........................................ ................

8、................................. 66 4 Conclusion......................................................................................... 71 5 References ............................................... .................

9、....................... 72 Part 3 Comparative quantitative proteomics study of hepatocellular carcinoma subtypes with different tumor size .................... ... ... .... ... 79 1 Materials and methods ................

10、.............. ....................................... 80 2 Results ................................................ ............................................. 91 3 Discussion................................ .........

11、.............................................. 119 4 Conclusion..................................... ................................................. 126 5 References ....................................................

12、.................................. 127 Part 4 Expression and clinical significance of HK2 in hepatocellular carcinoma ....................................................................................... ... 134 1 Mate

13、rials and methods .................................................................... 134 2 Results ................................................ ........................................... 136 福建醫(yī)科大學(xué)博士學(xué)位論文 APPENDIX

14、English Abbreviations English acronyms English name HCC hepatocellular carcinoma HBV hepatitis B virus AFP alpha fetoprotein TBIL total bilirubin MVI microscopic vascular invasion iTRAQ isobaric tags for relativ

15、e and absolute quantification MS mass spectrometry nano-LC-MS/MS nano-liquid chromatography-tandem mass spectrometry 2D LC-MS/MS two dimensional liquid chromatography-tandem mass spectrometry UPLC ultra performance

16、 liquid chromatography HCD high energy collisional dissociation qPCR real-time quantitative polymerase chain reaction WB Western Blot PBS phosphate buffered saline TEAB triethylammonium bicarbonate HRP horseradis